Provides an all-in-one solution for antimicrobial resistance (AMR) data analysis in a One Health approach
-Peer-reviewed, used in over 175 countries, available in 28 languages
+Peer-reviewed, used in over 175 countries, cites over 100 times, available in 28 languages
Generates antibiograms - WISCA for empiric coverage estimates, or traditional/syndromic for AMR surveillance
Provides the full microbiological taxonomy of ~97 000 distinct species and extensive info of ~620 antimicrobial drugs
Applies CLSI 2011-2026 and EUCAST 2011-2026 clinical and veterinary breakpoints, and ECOFFs, for MIC and disk zone interpretation
@@ -120,6 +120,7 @@
Since its first public release in early 2018, this R package has been used in almost all countries in the world. Click the map to enlarge and to see the country names.
With the help of contributors from all corners of the world, the AMR package is available in English, Arabic, Bengali, Chinese, Czech, Danish, Dutch, Finnish, French, German, Greek, Hindi, Indonesian, Italian, Japanese, Korean, Norwegian, Polish, Portuguese, Romanian, Russian, Spanish, Swahili, Swedish, Turkish, Ukrainian, Urdu, and Vietnamese. Antimicrobial drug (group) names and colloquial microorganism names are provided in these languages.
+
The AMR package was cited over 100 times in scientific research.
@@ -191,9 +192,9 @@
Piperacillin/tazobactam + Tobramycin
-
70% (64.7-75.2%)
-
93.6% (92.2-95.1%)
-
89.8% (87-92.5%)
+
69.9% (64.9-75.3%)
+
93.6% (92.1-95%)
+
89.9% (87-92.4%)
WISCA supports stratification by any clinical variable, so you can generate syndrome-specific or ward-specific coverage estimates:
@@ -219,21 +220,21 @@
Clinical
-
74.6% (68.6-80.6%)
-
93.7% (92.1-95.1%)
-
90.4% (87-93.1%)
+
74.5% (68.6-80.5%)
+
93.7% (91.7-95.1%)
+
90.4% (87.1-93.1%)
ICU
-
57% (48.6-65.7%)
-
86.8% (83.6-89.8%)
-
82.9% (78.1-87.3%)
+
57% (48.6-65.6%)
+
86.7% (83.3-89.9%)
+
83% (78.1-87.5%)
Outpatient
-
56.9% (45.9-68.2%)
-
76.7% (70.6-82.3%)
-
68% (57.6-77.2%)
+
57.4% (46-69.1%)
+
76.7% (70.5-82.7%)
+
67.7% (57.3-77.4%)
@@ -391,11 +392,6 @@
summarise(across(c(GEN, TOB),list(total_R =resistance, conf_int =function(x)sir_confidence_interval(x, collapse ="-"))))
-#> ℹ `resistance()` assumes the EUCAST guideline and thus
-#> considers the 'I' category susceptible. Set the `guideline`
-#> argument or the `AMR_guideline` option to either "CLSI" or
-#> "EUCAST", see `?AMR-options`.
-#> ℹ This message will be shown once per session.#> # A tibble: 3 × 5#> ward GEN_total_R GEN_conf_int TOB_total_R TOB_conf_int#> <chr> <dbl> <chr> <dbl> <chr>
diff --git a/index.md b/index.md
index 00b7953f0..ef163eaff 100644
--- a/index.md
+++ b/index.md
@@ -2,8 +2,8 @@
- Provides an **all-in-one solution** for antimicrobial resistance (AMR)
data analysis in a One Health approach
-- **Peer-reviewed**, used in over 175 countries, available in 28
- languages
+- **Peer-reviewed**, used in over 175 countries, cites over 100 times,
+ available in 28 languages
- Generates **antibiograms** - WISCA for empiric coverage estimates, or
traditional/syndromic for AMR surveillance
- Provides the **full microbiological taxonomy** of ~97 000 distinct
@@ -89,6 +89,10 @@ Swahili,  Swedish,  Turkish,
Vietnamese. Antimicrobial drug (group) names and colloquial
microorganism names are provided in these languages.
+The `AMR` package was cited [over 100
+times](https://scholar.google.com/citations?view_op=view_citation&hl=en&citation_for_view=sAoHvIgAAAAJ:0EnyYjriUFMC)
+in scientific research.
+
## Practical examples
### Filtering and selecting data
@@ -183,7 +187,7 @@ wisca(example_isolates,
| Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:---|:---|:---|
-| 70% (64.7-75.2%) | 93.6% (92.2-95.1%) | 89.8% (87-92.5%) |
+| 69.9% (64.9-75.3%) | 93.6% (92.1-95%) | 89.9% (87-92.4%) |
WISCA supports stratification by any clinical variable, so you can
generate syndrome-specific or ward-specific coverage estimates:
@@ -199,9 +203,9 @@ wisca(example_isolates,
| Syndromic Group | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:---|:---|:---|:---|
-| Clinical | 74.6% (68.6-80.6%) | 93.7% (92.1-95.1%) | 90.4% (87-93.1%) |
-| ICU | 57% (48.6-65.7%) | 86.8% (83.6-89.8%) | 82.9% (78.1-87.3%) |
-| Outpatient | 56.9% (45.9-68.2%) | 76.7% (70.6-82.3%) | 68% (57.6-77.2%) |
+| Clinical | 74.5% (68.6-80.5%) | 93.7% (91.7-95.1%) | 90.4% (87.1-93.1%) |
+| ICU | 57% (48.6-65.6%) | 86.7% (83.3-89.9%) | 83% (78.1-87.5%) |
+| Outpatient | 57.4% (46-69.1%) | 76.7% (70.5-82.7%) | 67.7% (57.3-77.4%) |
**For AMR surveillance**, traditional antibiograms remain the right tool
for tracking resistance per species over time:
@@ -310,11 +314,6 @@ example_isolates %>%
summarise(across(c(GEN, TOB),
list(total_R = resistance,
conf_int = function(x) sir_confidence_interval(x, collapse = "-"))))
-#> ℹ `resistance()` assumes the EUCAST guideline and thus
-#> considers the 'I' category susceptible. Set the `guideline`
-#> argument or the `AMR_guideline` option to either "CLSI" or
-#> "EUCAST", see `?AMR-options`.
-#> ℹ This message will be shown once per session.
#> # A tibble: 3 × 5
#> ward GEN_total_R GEN_conf_int TOB_total_R TOB_conf_int
#>
diff --git a/llms.txt b/llms.txt
index 1b703546a..fa9958d46 100644
--- a/llms.txt
+++ b/llms.txt
@@ -2,8 +2,8 @@
- Provides an **all-in-one solution** for antimicrobial resistance (AMR)
data analysis in a One Health approach
-- **Peer-reviewed**, used in over 175 countries, available in 28
- languages
+- **Peer-reviewed**, used in over 175 countries, cites over 100 times,
+ available in 28 languages
- Generates **antibiograms** - WISCA for empiric coverage estimates, or
traditional/syndromic for AMR surveillance
- Provides the **full microbiological taxonomy** of ~97 000 distinct
@@ -89,6 +89,10 @@ Swahili,  Swedish,  Turkish,
Vietnamese. Antimicrobial drug (group) names and colloquial
microorganism names are provided in these languages.
+The `AMR` package was cited [over 100
+times](https://scholar.google.com/citations?view_op=view_citation&hl=en&citation_for_view=sAoHvIgAAAAJ:0EnyYjriUFMC)
+in scientific research.
+
## Practical examples
### Filtering and selecting data
@@ -183,7 +187,7 @@ wisca(example_isolates,
| Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:---|:---|:---|
-| 70% (64.7-75.2%) | 93.6% (92.2-95.1%) | 89.8% (87-92.5%) |
+| 69.9% (64.9-75.3%) | 93.6% (92.1-95%) | 89.9% (87-92.4%) |
WISCA supports stratification by any clinical variable, so you can
generate syndrome-specific or ward-specific coverage estimates:
@@ -199,9 +203,9 @@ wisca(example_isolates,
| Syndromic Group | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:---|:---|:---|:---|
-| Clinical | 74.6% (68.6-80.6%) | 93.7% (92.1-95.1%) | 90.4% (87-93.1%) |
-| ICU | 57% (48.6-65.7%) | 86.8% (83.6-89.8%) | 82.9% (78.1-87.3%) |
-| Outpatient | 56.9% (45.9-68.2%) | 76.7% (70.6-82.3%) | 68% (57.6-77.2%) |
+| Clinical | 74.5% (68.6-80.5%) | 93.7% (91.7-95.1%) | 90.4% (87.1-93.1%) |
+| ICU | 57% (48.6-65.6%) | 86.7% (83.3-89.9%) | 83% (78.1-87.5%) |
+| Outpatient | 57.4% (46-69.1%) | 76.7% (70.5-82.7%) | 67.7% (57.3-77.4%) |
**For AMR surveillance**, traditional antibiograms remain the right tool
for tracking resistance per species over time:
@@ -310,11 +314,6 @@ example_isolates %>%
summarise(across(c(GEN, TOB),
list(total_R = resistance,
conf_int = function(x) sir_confidence_interval(x, collapse = "-"))))
-#> ℹ `resistance()` assumes the EUCAST guideline and thus
-#> considers the 'I' category susceptible. Set the `guideline`
-#> argument or the `AMR_guideline` option to either "CLSI" or
-#> "EUCAST", see `?AMR-options`.
-#> ℹ This message will be shown once per session.
#> # A tibble: 3 × 5
#> ward GEN_total_R GEN_conf_int TOB_total_R TOB_conf_int
#>
diff --git a/news/index.html b/news/index.html
index 195969010..797852ed1 100644
--- a/news/index.html
+++ b/news/index.html
@@ -7,7 +7,7 @@
AMR (for R)
- 3.0.1.9081
+ 3.0.1.9082
@@ -49,15 +49,15 @@
-
AMR 3.0.1.9081
+
AMR 3.0.1.9082
Planned as v3.1.0, end of June 2026.
-
Breaking Changes
+
Breaking Changes
The former kingdoms Bacteria and Archaea are now each divided into four kingdoms with new top-level domains ‘Bacteria’ and ‘Archaea’ (Göker and Oren, 2024, DOI: 10.1099/ijsem.0.006242). Following this, a new domain column in the microorganisms data set was added, and more importantly, mo_kingdom() now returns the formal kingdom (e.g. "Pseudomonadati" instead of "Bacteria"). Use mo_domain() for the old behaviour. For non-prokaryotic kingdoms (Fungi, Protozoa, etc.), kingdom and domain are identical.
Faster parallel computing via the future package for as.sir() and wisca(): a non-sequential plan (e.g. future::plan(future::multisession)) must be active before using parallel = TRUE.
-
New
+
New
EUCAST 2026 and CLSI 2026 breakpoints: over 5,700 new breakpoints added to the clinical_breakpoints data set; EUCAST 2026 is now the default for all MIC and disk diffusion interpretations
Wildtype/Non-wildtype (WT/NWT) output when using ECOFF-based interpretation, by setting breakpoint_type = "ECOFF" in as.sir(); WT/NWT results are fully supported in all resistance/susceptibility functions and plots (#254)
@@ -74,7 +74,7 @@
New wisca_plot() to assess the susceptibility and incidence distributions from the Monte Carlo simulations
top_n_microorganisms(): new property_for_each argument for sub-grouping within top n groups; rank ordering enforced (only lower taxonomic ranks allowed); fixed property = NULL not being accepted; inner filter now tracks original row indices to prevent cross-group contamination
Taxonomic update for all microorganisms, now updated to June 2026